MAPK3 and neoplasm: In tumor endothelial cells, FGF2 switches the TGFβ endothelial-to-myothelial program to differentiate into active fibroblastic cells through activation of E26 transcription factor ELK1, a downstream target of ERK1/2 activation [334].